Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?

@inproceedings{Watermann2015ImprovedDT,
  title={Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?},
  author={Iris Watermann and Beate M. Schmitt and Florian Stellmacher and Julia Mueller and Rania Gaber and Ch. Kugler and Niels Reinmuth and R. M. Huber and Michael Thomas and Peter Zabel and Klaus Friedrich Rabe and Danny Jonigk and Arne Warth and Ekkehard Vollmer and Martin Reck and Torsten Goldmann},
  booktitle={Diagnostic pathology},
  year={2015}
}
BACKGROUND Several c-MET targeting inhibitory molecules have already shown promising results in the treatment of patients with Non-small Cell Lung Cancer (NSCLC). Combination of EGFR- and c-MET-specific molecules may overcome EGFR tyrosine kinase inhibitor (TKI) resistance. The aim of this study was to allow for the identification of patients who might benefit from TKI treatments targeting MET and to narrow in on the diagnostic assessment of MET. METHODS 222 tumor tissues of patients with… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 8 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • 2016
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 45 references

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.

Annals of oncology : official journal of the European Society for Medical Oncology • 2009
View 4 Excerpts
Highly Influenced

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.

Proceedings of the National Academy of Sciences of the United States of America • 2007
View 5 Excerpts
Highly Influenced

First-line crizotinib in ALK-positive lung cancer.

The New England journal of medicine • 2015
View 1 Excerpt

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2013

Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2.

Proceedings of the National Academy of Sciences of the United States of America • 2013

Similar Papers

Loading similar papers…